• Increase font size
  • Default font size
  • Decrease font size
Home HPV and Men HPV and Men Research Finds Gardasil® is Effective in Men

Research Finds Gardasil® is Effective in Men

E-mail Print PDF

Data from a large international study suggest Gardasil® is effective in preventing genital lesions and persistent HPV infections in men.

A team of researchers led by Heiko Jessen, M.D. of Germany randomized 4,065 men (602 men who have sex with men, the rest heterosexual) between the ages of 16-26 into vaccine and placebo groups. Among subjects in the per-protocol vaccine group (those who adhered to the study guidelines and received all doses of the vaccine), the vaccine was 90.4% effective in preventing external genital lesions. Only three cases of lesions were found among subjects receiving the vaccine, compared with 31 cases in the placebo group. The lesions detected were primarily genital warts and – among those who received the vaccine- no cases of penile, perianal, or perineal precancers were found. MaleVac

Also, a separate analysis of men who have sex with men (MSM) in the study found the vaccine reduced anal precancers by nearly 78%.

Overall, persistent infections were reduced by 85.6% among subjects who were vaccinated. With the per-protocol subjects, the vaccine was nearly 48% effective in preventing persistent infections.

Gardasil® protects against four types of HPV, including the two “low risk” types most often found with anogenital warts and two “high risk” types found in a number of HPV-related anogenital cancers. While currently only approved for use in men to prevent genital warts, data such as these may eventually lead the vaccine to also be recommended for the prevention of other diseases (including anogenital cancers) in males.

The data were presented in July 2010 at the XVIII International AIDS Conference in Vienna.

Heiko Jessen, et al. Quadrivalent HPV vaccine efficacy against HPV 6/11/16/18 infection and disease in men. Abstract THLBB101 presented at the XVIII International AIDS Conference. July 2010, Vienna, Austria.